Metaplastic breast carcinomas are basal-like tumours

• Tipo: Artigo em Revista Científica Internacional
• Data: 2006

Autores

Reis, JS (Autor) Outra; Milanezi, F (Autor) Outra; Steele, D (Autor) Outra; Savage, K (Autor) Outra; Simpson, PT (Autor) Outra; Nesland, JM (Autor) Outra; Pereira, EM (Autor) Outra; Lakhani, SR (Autor) Outra; Fernando Schmitt (Autor) FMUP

Revista

Título: Histopathology

Vol. 49

Páginas: 10-21

ISSN: 0309-0167

Editora: Wiley-Blackwell

Indexação

ISI Web of Knowledge - 252 Citações

Scopus - 280 Citações

Outras Informações

ID Authenticus: P-004-JTR

DOI: 10.1111/j.1365-2559.2006.02467.x

Abstract (EN): Aims: Recently, an immunohistochemical panel comprising antibodies against HER2, oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6 was reported to identify basal-like breast carcinomas, as defined by cDNA microarrays. Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype. Methods and results: Sixty-five cases were retrieved from the pathology archives of the authors' institutions and reviewed by three of the authors. Immunohistochemistry with antibodies for HER2, ER, EGFR, CK5/6, CK14 and p63 was performed according to standard methods. All but six cases (91%) showed the typical immunoprofile of basal-like tumours (ER- and HER2-, EGFR+ and/or CK5/6+). When CK14 and p63 were added to the panel, two additional cases could be classified as basal-like. The majority of MBCs lacked PR, except 4/19 (21%) carcinomas with squamous metaplasia. Conclusions: Our results demonstrate that MBCs show a basal-like phenotype, regardless of the type of metaplastic elements. Moreover, as these neoplasms frequently overexpress EGFR (57%), patients with MBC may benefit from treatment with anti-EGFR drugs.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 12